Major Review Finds Alzheimer’s Amyloid Drugs Offer No Real Benefit

A major review challenges a long-standing strategy in Alzheimer’s research, suggesting that removing a hallmark brain protein ...
Morning Overview on MSN

Review finds GLP-1 weight-loss drugs may cut Alzheimer’s amyloid and tau

Drugs best known for helping people lose weight may also chip away at the proteins that define Alzheimer’s disease. A ...

Weight-Loss Drugs May Reduce Buildup of Alzheimer's Proteins, Major Review Finds

The review by researchers at Anglia Ruskin University in the UK looked at 30 published studies conducted in cell cultures and ...
Psychiatry Advisor

Amyloid-Beta-Targeted MAbs Have Little Impact in MCI, Mild Alzheimer Disease Dementia

Amyloid-beta-targeted monoclonal antibodies had negligible effects for adults with mild cognitive impairment or AD-related dementia.
The BMJ

Alzheimer’s drugs targeting amyloid do not produce clinically meaningful effects, concludes Cochrane review

Alzheimer’s drugs targeting amyloid β proteins “do not produce clinically meaningful positive effects” and slightly increase the risk of swelling and bleeding in the brain, an independent Cochrane ...
The Cardiology Advisor

FDA Fast-Tracks Coramitug, an Amyloid-Depleting Therapy for ATTR-CM

Coramitug is currently being investigated in the phase 3 CLEOPATTRA trial in approximately 1280 patients with ATTR-CM.
STAT

Cochrane review reignites Alzheimer’s amyloid wars

Also, a sweeping Cochrane review is fueling fresh debate over amyloid-targeting Alzheimer’s drugs. And more.  The Food and ...
News-Medical.Net

Clearing amyloid beta shows no significant impact on dementia severity

Drugs that target amyloid beta proteins in the brain likely have no clinically meaningful positive effects, while increasing the risk of bleeding and swelling in the brain, a new Cochrane review has ...

Anti-amyloid drugs may not work against Alzheimer's but if so, what will?

Anti-amyloid drugs may not have a clinically meaningful effect in the treatment of Alzheimer's disease, a new review says. So ...
STAT

There is no ‘amyloid cabal’ in Alzheimer’s research

Selkoe is co-director of the Ann Romney Center for Neurologic Diseases, Department of Neurology, Mass General Brigham, and Vincent and Stella Coates professor of neurologic diseases at Harvard Medical ...